Tumour cells will be grown as monolayer at 37°C in a humidified atmosphere (5% CO2, 95% air). DMEM (ref: BE12-604F, Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (ref: 3302, Lonza) and 1% penicillin streptomycin (ref: DE-17-602F, Lonza, Verviers, Belgium). The cells are adherent to plastic flasks. For experimental use, tumour cells will be detached from the culture flask by a 5 minute treatment with trypsin-versene (ref: BE02-007E, Lonza) at 37°C, in Hanks’ medium without calcium or magnesium (ref: BE10-543F, Lonza) and neutralized by addition of complete culture medium. The cells will be counted in a hemocytometer and their viability will be assessed by 0.25% trypan blue exclusion assay.

Download the complete PDF document here : BIOMIMESYS® hydroscaffold subcutaneous implantation_20180411


gregory

gregory

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: